Australia markets open in 16 minutes

Telix Pharmaceuticals Limited (TLPPF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
6.30+0.20 (+3.28%)
At close: 10:51AM EST
Full screen
Trade prices are not sourced from all markets
Previous close6.10
Open6.26
BidN/A x N/A
AskN/A x N/A
Day's range6.26 - 6.30
52-week range2.75 - 6.30
Volume1,250
Avg. volume2,837
Market cap1.8B
Beta (5Y monthly)2.32
PE ratio (TTM)N/A
EPS (TTM)-0.16
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Telix Collaborates with Olivia Newton-John Cancer Research Institute on Brain Cancer Imaging Study

    MELBOURNE, Australia, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into a clinical data access agreement with the Olivia Newton-John Cancer Research Institute (ONJCRI) relating to a prospective clinical trial investigating the use of O-(2-[18F]fluoroethyl)-L-tyrosine or 18F-FET to image glioblastoma patients with positron emission tomography (PET) (FET-PET). 18F-FET is under development by Telix (referred to as

  • GlobeNewswire

    First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer

    MELBOURNE, Australia and NANTES, France, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and Nantes-based ATONCO S.A.S. (‘ATONCO’) today announce that a first patient has been dosed in a Phase I study of TLX250-CDx in patients with non-muscle-invasive bladder cancer (NMIBC) at the Institut de Cancérologie de l’Ouest (ICO) in St Herblain, France. The objective of ‘PERTINENCE1’ an investigator-led, open-label, proof of concept study, is to evaluate sa

  • GlobeNewswire

    FDA Approves Telix’s Prostate Cancer Imaging Product, Illuccix®

    MELBOURNE, Australia and INDIANAPOLIS, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company), a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on molecularly targeted radiation (MTR), today announces that the United States Food and Drug Administration (FDA) has approved Telix’s lead prostate cancer imaging product, Illuccix®. Illuccix is a kit for the preparation of gallium-68 (68Ga) gozetotide (al